Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / INMB - INmune Bio: Still A Bargain If Their Alzheimer's Program Reaches Its Inflection

INMB - INmune Bio: Still A Bargain If Their Alzheimer's Program Reaches Its Inflection

INmune Bio Inc.

2024-07-05 09:57:38 ET

Summary

  • INmune Bio focuses on late-stage therapy for Alzheimer's disease and natural killer cell therapy.
  • XPro is the main focus for Alzheimer's disease, showing promising results with ongoing phase 2 study.
  • Financially, INMB faces cash challenges but continues to make progress with a potential transformative data readout by spring 2024.

Topline Summary and Update

For further details see:

INmune Bio: Still A Bargain If Their Alzheimer's Program Reaches Its Inflection
Stock Information
Company Name: INmune Bio Inc.
Stock Symbol: INMB
Market: NASDAQ
Website: inmunebio.com
Menu
INMB INMB Quote INMB Short INMB News INMB Articles INMB Message Board
Get INMB Alerts

News, Short Squeeze, Breakout and More Instantly...